Business Wire

DANTE-LABS

10.10.2019 12:13:07 CEST | Business Wire | Press release

Share
Now You Can Get Your Whole Genome Sequenced in Only 2 Weeks With Dante Labs

Dante Labs announced today the official launch of its premium 2-week turnaround time for its whole genome sequencing tests. On average, genetics labs in Europe, Asia and the United States offer turnaround times between six to ten weeks, and just for the raw data. Dante Labs offers reports and raw data within two weeks from receiving the sample back.

The new service is possible thanks to the new Illumina-backed, high-throughput, automated sequencing centre that Dante Labs built in Italy, fully dedicated to the classical Whole Genome and the WholeGenomeZ™ sequencing tests.

“It is a huge difference to have our own sequencing centre.” Dante Labs CEO Andrea Riposati says. “We thought we could offer best in class service by externalizing the sequencing to third party labs. Through our initial model, thousands of people received their full whole genome results at affordable prices, receiving a full picture of their DNA for the first time in their life, often after years of guessing and after life-long undiagnosed odysseys. However, in the last twelve months about 20% of our users experienced delays – in some cases significant ones – because of delays from third party labs. Now, we can go from being criticized as ‘too slow’ to providing first-class sequencing speed matched with the first-class quality of our sequencing lab. If someone needs an urgent whole genome sequencing, we are the go-to-company.”

In order to ensure everyone received results on time and is also fully aware of the status of its samples, Dante Labs made significant investments in the last four months:

  • Dante Labs built its own high-throughput sequencing center in L’Aquila, Italy, a 900-square meter GDPR-compliant, certified facility;
  • Dante Labs fully internalized its non-US logistics in Italy and selected a new, best-in-class fulfilment partner in North America;
  • Dante Labs developed a clearer messaging system to alert individuals about the status of their samples, including visual widgets and smart automated emails, personalized for family members who registered multiple kits and ordered multiple reports;

The price of the Premium Whole Genome is €899 (or $949) for the fast turnaround time vs. €599 (or $649) for the standard turnaround time. The price for the Super Premium WholeGenomeZ is €1399 (or $1499) for the fast turnaround time, and €899 (or $999) for the standard turnaround time.

These prices are still way below what individuals are forced to pay by offline labs across Europe, North America, South America, Oceania and Asia.

About Dante Labs

Dante Labs is global genetic testing and data analysis company specialized in whole genome sequencing and interpretation. To learn more or to purchase a Dante Labs whole genome sequencing test, visit www.dantelabs.com and follow @DanteLabs , or visit our YouTube Channel .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mobix Labs Signs Definitive Agreement to Acquire Vision Aerial, Accelerating Global Drone Platform for National Security and Aerial Intelligence24.7.2026 13:00:00 CEST | Press release

Transaction accelerates Mobix Labs’ global aerial intelligence strategy and National Security Matters Initiative Mobix Labs, Inc. (Nasdaq: MOBX) today announced that it has signed a definitive agreement to acquire Vision Aerial, Inc., a U.S.-based designer and manufacturer of American-built, National Defense Authorization Act (NDAA)-compliant unmanned aerial systems. The definitive agreement moves the transaction beyond the previously announced letter of intent and represents a major step toward closing an acquisition that would expand Mobix Labs into one of the world’s most important technology growth markets: secure drones, autonomous aerial systems and aerial intelligence for national security, critical infrastructure, energy, public safety, industrial inspection and government operations. Vision Aerial’s customers and end-users include the U.S. Air Force, U.S. Navy, government agencies, energy and utility operators, research institutions and other organizations requiring performanc

Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer24.7.2026 13:00:00 CEST | Press release

Recommendation based on DESTINY-Breast09 phase 3 trial results that showed Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% versus THP with a median progression-free survival exceeding three years If approved, Daiichi Sankyo and AstraZeneca’s Enhertu plus pertuzumab would become first new treatment in the EU in more than a decade for first-line HER2 positive metastatic breast cancer Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been recommended for approval in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP)

SLB Announces Second-Quarter 2026 Results24.7.2026 12:50:00 CEST | Press release

Revenue of $8.97 billion increased 3% sequentially and 5% year on year GAAP EPS of $0.52 increased 4% sequentially and decreased 30% year on year EPS, excluding charges and credits, of $0.55 increased 6% sequentially and decreased 26% year on year Net income attributable to SLB of $786 million increased 5% sequentially and decreased 22% year on year Adjusted EBITDA of $1.90 billion increased 7% sequentially and decreased 7% year on year Cash flow from operations was $1.36 billion and free cash flow was $716 million Board approved quarterly cash dividend of $0.295 per share SLB (NYSE: SLB) today announced results for the second-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722694386/en/ The exterior of the SLB headquarters in Houston, Texas.Second-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeJun. 30, 2026Mar. 31, 2026Jun. 30, 2025SequentialYear-on-yearRevenue $8,972 $8

NIQ Expands GenAI Capabilities Across gfknewron, Turning Trusted Intelligence into Decisions Faster24.7.2026 12:30:00 CEST | Press release

New capabilities help businesses uncover trends faster, simplify complex analysis, and accelerate confident decision-making NIQ (NYSE: NIQ), a leader in consumer intelligence, today announced the expansion of AI-powered Smart Insights across its gfknewron® platform. By bringing together markets and categories into a single view, gfknewron enables businesses to transform complex market, consumer and supply chain data into clear, actionable intelligence quickly. The latest enhancements help users identify trends, opportunities and performance drivers more quickly, reducing the time required to analyze large datasets and accelerating confident decision-making across teams. As brands and retailers face growing pressure to respond quickly to changing consumer behavior and market dynamics, the ability to unlock meaningful insights from increasingly rich datasets has become a significant competitive advantage. As AI is only as effective as the intelligence behind it, Smart Insights helps busi

Thales to Strengthen Romania’s Airspace Protection With Twelve Ground Master 200 MM/A Radars24.7.2026 10:05:00 CEST | Press release

The Romanian General Directorate for Armaments and the French Direction Générale de l’Armement (DGA – the French defence procurement agency) have signed an agreement to supply twelve Thales GM200 Multi-Mission All-in-one (GM200 MM/A) radars to protect the Romanian airspace. This government-to-government agreement underlines the high level of partnership between France and Romania, within the framework of the European Union’s SAFE funding programme, in order to bolster Europe’s defence capabilities. The GM200 MM/A is part of Thales’ proven Ground Master radar family, which has already been deployed in over 40 countries, including now in Romania. In a context of growing collaboration between European nations to bolster collective security, the Romanian General Directorate for Armaments has just signed a landmark agreement with France’s Direction Générale de l’Armement (DGA) to acquire twelve Thales Ground Master 200 Multi-Mission All-in-one (GM200 MM/A) radars. This government-to-governm

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye